title: Early detection of ovarian cancer: preliminary results of the Yale Early Detection Program.
abstract: Eighty-four women at high risk for ovarian cancer by having first-degree relatives with epithelial ovarian cancer participated in a newly established, early ovarian cancer detection program at Yale University. Participants were to be evaluated with physical examinations and circulating tumor markers at entry and every six months thereafter. Endovaginal ultrasound and color Doppler flow studies were to be performed at three and nine months following entry into the program. In addition, women were encouraged to follow American Cancer Society guidelines for mammography. Stool was checked for occult blood. Endometrial sampling was offered to post-menopausal women. No participant has developed an ovarian cancer since entering the program. One woman has been diagnosed to have breast cancer. False-positive levels of circulating tumor markers (CA 125, 4/84 [4.8 percent]; lipid-associated sialic acid in plasma, 13/84 [15.5 percent]; NB/70K, 4/84 [4.8 percent]; and urinary gonadotropin fragment, 1/65 [1.5 percent]) were observed on entry into the program. Low resistive indices (less than 0.5) were documented in 8/91 (8.8 percent) ovaries studied by the color Doppler flow technique. One participant underwent a laparotomy based on a false-positive endovaginal ultrasound examination. Tests now being employed in community practice have a high likelihood of being associated with false-positive results. Therapeutic interventions based on isolated abnormal tumor markers or ultrasound studies obtained from women with family histories of ovarian cancer may lead to inappropriate surgery. It is necessary for cancer centers to develop expertise in ovarian cancer detection techniques to advise physicians in their geographic areas appropriately about the significance of the abnormal screening test.
authors.affiliation: Department of Obstetrics and Gynecology, Yale University School of Medicine, New Haven, CT 06510.
authors.forename: P E
authors.initials: PE
authors.lastname: Schwartz
authors.forename: J T
authors.initials: JT
authors.lastname: Chambers
authors.forename: K J
authors.initials: KJ
authors.lastname: Taylor
authors.forename: J
authors.initials: J
authors.lastname: Pellerito
authors.forename: L
authors.initials: L
authors.lastname: Hammers
authors.forename: L A
authors.initials: LA
authors.lastname: Cole
authors.forename: T L
authors.initials: TL
authors.lastname: Yang-Feng
authors.forename: P
authors.initials: P
authors.lastname: Smith
authors.forename: S T
authors.initials: ST
authors.lastname: Mayne
authors.forename: R
authors.initials: R
authors.lastname: Makuch
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood; D005260:Female; D006801:Humans; D008403:Mass Screening; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000175:diagnosis* / Q000000981:diagnostic imaging; D014463:Ultrasonography
chemical_list: D014408:Biomarkers, Tumor